HER2 Testing and the Utility of Ki67
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.
Clinical Pearls
- Recent ASCO-CAP guidelines lay out what is considered to be HER2 positive, negative, or equivocal.
- HER2 testing should be done in high volume, well-equipped, quality-assured pathology centers.
- The role for Ki67 as a prognostic marker is well-studied, though significant issues remain regarding its predictive utility and validity.
- These issues must be addressed before Ki67 is used routinely in clinical practice.
Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.
Related Videos
Related Content
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024Article
During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
